| Pharmaceutical Information |
| Drug Name |
Naloxegol |
| Drug ID |
BADD_D02467 |
| Description |
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier. |
| Indications and Usage |
Indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. |
| Marketing Status |
Not Available |
| ATC Code |
A06AH03 |
| DrugBank ID |
DB09049
|
| KEGG ID |
D10479
|
| MeSH ID |
C000589308
|
| PubChem ID |
56959087
|
| TTD Drug ID |
D07LCF
|
| NDC Product Code |
Not Available |
| Synonyms |
naloxegol | Movantik | NKTR-118 |
|
| Chemical Information |
| Molecular Formula |
C34H53NO11 |
| CAS Registry Number |
854601-70-0 |
| SMILES |
COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
